Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I see eleven 1000 (code for don't let it run) bid/asks on Level II pre-market. Hopefully, the MMs won't be able to combat the buying pressure and volume, but I suspect the illegal manipulation to continue through MAA submission and MAA acceptance. A partnership/equity deal and subsequent up-listing after the MHRA approval is likely the only thing that will provide significant support.
Interesting to see his former CFO role at Cognate.
TTsr, just to add, I suspect that not all GBM patients will be cured like Brad Silver, and their treatment will need to be managed/ongoing. Also, my lack of cynicism is always tempered when I think about what JP Morgan once told Tesla, “If you can't put a meter on it, we don't want it.”
NOVN banked at SVB. More buying opportunities to come.
#psychobabble
PM, you stated that you “guessed” the month was removed on SM’s LinkedIn information at the company’s request and then concluded that the level of of lying and gas lighting by the company was astounding. I am astounded that any former executive would slander another executive based on a guess. My guess is that your constant disparagement of the company is because tearing down others covers your own insecurities concerning what a failure you were in your own career. I assume you are okay being on the receiving end of someone else’s guesses.
PM, I’d just like to add that while thalidomide wasn’t approved in the U.S., about 20,000 Americans were given this drug in the 50s and 60s during Richardson-Merrell and Smith, Kline & French’s two clinical trials.
Merck to stop phase 3 trial of Keytruda combo in prostate cancer on lack of survival benefit https://seekingalpha.com/news/3927649-merck-to-stop-phase-3-trial-of-keytruda-combo-in-prostate-cancer-on-lack-of-survival-benefit
From what I recall of his comments, I think you are reading too much into his statement when you added the “not to investors” part. IMO stating that a CEO has a fiduciary responsibility to a company doesn’t mean or imply they don’t also have a fiduciary responsibility to their shareholders, who of course are the owners of the company.
I got a Reddit hit using Safari.
Yes, I think it’s possible that the SP will continue to struggle, but I don’t see this resistance holding after Flashworks is approved for manufacturing and -L revenues start coming in, hopefully before year-end.
I assumed, perhaps wrongly, that other MMs not named as defendants would provide the same amount of liquidity.
Actually, that’s what I meant by “defendents’ NWBO trading activities”, so not a broad suspension. You’d think that would help our cause.
From a legal standpoint, I wonder what the likelihood is that the judge would suspend the defendants’ NWBO trading activities at some point until the lawsuit is resolved.
Good to see CDEL seemingly anti-spoofing on the ask at .74 pre-market. :)
Busy and sees no need. I suspect at least one party has already agreed to partner upon MHRA approval.
CRL is listed as a bronze sponsor, but I don’t see NWBO or Advent.
…for Europe and North America :)
Ex, I don’t think your take is accurate. She didn’t say that a strategic decision would be made regarding marketing approval applications with other RAs. Rather she said that they are approaching marketing approval applications with other RAs strategically, which is a positive comment, not a negative one, as it pertains to Project Orbis, etc. IMO.
Ouch. Get well soon.
Google’s search engine produces many DCVax info. links for “Dr. Ashkan cancer vaccine”. It’s probably better written this way in order to avoid a lawsuit.
AbbVie is another dark horse candidate IMO.
Can anyone confirm that they took the case on a contingency basis?
Sounds totally awesome. Enjoy your Hawaiian holiday!
I’m very optimistic as the forces aligned against NWBO are unable to stop the MIA, MAA, and NICE approvals, not to mention the lawsuit. Once MHRA approves 1Q or 2Q 2023, it’s the beginning of the end for those out to destroy us. From there, it could play out a number of different ways with different timelines, but the company will succeed and DCVax-L will continue to save lives. The decision makers at the RAs are certain to recognize that a benefit of an honest well-deserved approval is that it could end up saving their own lives or the lives of their loved ones. I believe this basic survival instinct will overcome any corrupt attempt to sabotage approvals.
Here’s a rebuttal to the original tweet.
Why do you say ‘post hoc’ when it clearly says in the publication “This is the first SAP that has been submitted for the Trial, and it is being submitted prior to Data Lock and unblinding of the study results.” What does ‘post hoc’ mean to you?
— Al Musella (@AlMusella) December 23, 2022
And yesterday on Twitter, @HenryMuney highlighted “Process: HTA [sic] 2022. The single technology appraisal (STA) process was introduced by NICE in 2005 as a means of undertaking “fast track” appraisals of single technologies, for single indications. Unlike the standard multiple technology appraisal (MTA) process, STA relies on a manufacturer evidence submission and an independent critique of that submission, rather than an independent analysis. https://www.sheffield.ac.uk/nice-dsu/methods-development/sta-process
Absolute worst case, faced with imminent bankruptcy, I hope Linda would be able to sell the company for a song rather than file bankruptcy. This would be in both management’s and shareholders’ best interests. I don’t think it’s likely but just worst casing it.
Funny, like Monty Python’s Flying Circus. You forgot to add, and then Ken Griffin runs for President.
Two thumbs up.
Yes, I’m aware of that, too. I’ve been in and out of OTLK twice so I’m not watching the share price as close now as I was before. I recall there being a significant share price rebound when the FDA announced their PDUFA date. I plan to get back in at a later date. Their $7.00 price target is holding up. You stated you’re holding the bag now, but I may miss a buyout announcement if that’s the path taken. Anyway, GL with your investment.
That’s right. Also, OTLK withdrew their first marketing application submission after the FDA identified some shortcomings, and the share price took a hit but eventually recovered after the resubmitted application was accepted. Therefore, for longs holding, it probably won’t make any difference if NWBO announces the submission or waits for the acceptance of the BLA/MAA with the FDA/MHRA.
Someone asked Mike Scott for clarification seven hours ago on LinkedIn, but he hasn’t replied. The question was asked in the thread of the NWBO article in The Guardian that he posted a month ago.
I don’t know enough about it to answer your question, but my sense is that only BO/JV/partnership and/or some kind of merger/spin-off will be the only way to get off the OTC and away from the illegally suppressed PPS in the near term. Otherwise, they go it alone, wait for revenues, lawsuit resolution, and additional dilution in the long term. Longs win either way, but I hope LP has already chosen the former strategy and is making it happen.
Here’s one:
“I was asked to share this here too so:
$NWBO's SEC Fail to Deliver Data is now up to date.
3,279,544 shares FTD in the 2nd half of November. This is rivalled only by both halves of May which together totalled 10,944,652
So total FTD (reported by SEC*) for the Year to Date: 19,840,261
*Dendreon article claimed SEC figures are v low.
Page 5: sec.gov/comments/s7-08-09/s...
Highly worth a read if you haven't already. What the MMs & HFs are trying to do to $NWBO is a carbon copy of what they succeeded to do with Dendreon. This cannot & will not happen!
So, taking an average monthly FTD over the course of the year to calculate December and + this to the total it gives us an est total for 2022:
21,643,921
Now extrapolating this out for the 14 years of the trial give us 303,014,895
PLUS the the "legal" short position as it stands of +38,579,900 (likely ++ after the past 2 weeks)
Means that there is an $NWBO short position for these pricks to cover of AT LEAST ~340 MILLION!
Bullish”
https://stocktwits.com/TommBa/message/501611804
Same here when using my iPhone. A quick refresh on the URL solves the problem.
That’s so true. In my professional experience, I had colleagues in different positions than mine who had no idea what how busy I was carrying out day-to-day duties and special-project responsibilities, and I worked alongside them everyday in the same unit/organization. For anyone to say that NWBO management isn’t doing anything is naive.
This question was answered awhile back. My understanding is that it’s to increase the amount of authorized shares to cover outstanding warrants and options that haven’t been converted, and may not be converted anytime soon. Therefore, this action should not be interpreted as evidence that partnerships are not being negotiated.